Menu
340B drug pricing program stakeholders cheered on U.S. Sen. John Boozman's (R-Ark.) addition to the bipartisan Senate working group that’s drafting long-awaited 340B reform legislation.

340B Stakeholders Cheer the Addition of Sen. Boozman to 340B Working Group

Luke Zarzecki, National Correspondent 340B Report Views
340B drug pricing program stakeholders—from both sides of the debate over its future—cheered on the May 14 addition of an [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Post Navigation

Novo Nordisk Exempts 10 States from In-House Claims Data Reqs, Merck Exempts Washington from CP Restrictions, Reimplements Them in Three States 

Key 340B Critic Loses Reelection Bid in Louisiana GOP U.S. Senate Primary

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Site Footer Live